EUVIMEDEUVIMED entdecken
Open Access

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

Wei Wei iD, Ondrej Blaha iD, Denise Esserman iD, Daniel Zelterman, Michael Kane iD, Rachael Liu iD, Jianchang Lin iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Wei Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Bayes Theorem, Computer Simulation, Randomized Controlled Trials as Topic, Models, Statistical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enrolling patients to the standard of care (SOC) arm in randomized clinical trials, especially for rare diseases, can be very challenging due to the lack of resources, restricted patient population availability, and ethical considerations. As the therapeutic effect for the SOC is often well documented in historical trials, we propose a Bayesian platform trial design with hybrid control based on the multisource exchangeability modelling (MEM) framework to harness historical control data. The MEM approach provides a computationally efficient method to formally evaluate the exchangeability of study outcomes between different data sources and allows us to make better informed data borrowing decisions based on the exchangeability between historical and concurrent data. We conduct extensive simulation studies to evaluate the proposed hybrid design. We demonstrate the proposed design leads to significant sample size reduction for the internal control arm and borrows more information compared to competing Bayesian approaches when historical and internal data are compatible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bayes TheoremComputer SimulationRandomized Controlled Trials as TopicModels, StatisticalHumansSample SizeResearch DesignAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Bayesian adaptive designshistorical datainformative priorplatform trialrare disease

Autor:innen und Institutionen

  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Statistical & Quantitative Sciences, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.

ORCID-Profile: Wei Wei, Ondrej Blaha, Denise Esserman, Michael Kane, Rachael Liu, Jianchang Lin

Förderung

  • NIDCR NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Wei, W., Blaha, O., Esserman, D., Zelterman, D., Kane, M., Liu, R., & Lin, J. (2024). A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in Medicine. https://doi.org/10.1002/sim.10077

Vancouver

Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, et al. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in Medicine. 2024. doi:10.1002/sim.10077

BibTeX
@article{Wei2024,
  author = {Wei, Wei and Blaha, Ondrej and Esserman, Denise and Zelterman, Daniel and Kane, Michael and Liu, Rachael and Lin, Jianchang},
  title = {A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10077}
}
Kostenlos starten →